Hugel, Inc. (145020.KQ)

208,500.00 +500.00 (+0.24%) As of 12:41PM KST. Market open.

Hugel, Inc.

61-20, Sinbuk-ro
Sinbuk-eup
Chuncheon-si 24206
South Korea
82 3 3255 3882
https://www.hugel.co.kr

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ji-hoon Sohn	CEO & Executive Director	N/A	N/A	N/A
J. T. Kim	MD & CFO	N/A	N/A	N/A
Seonho Han	VP and Chief Sales & Marketing Officer	N/A	N/A	N/A
Mr. Soon-Woo Kwon	VP & Chief Production Officer	N/A	N/A	1970
Jennifer Rho	MD & Chief Strategy Officer	N/A	N/A	N/A
Minjong Kang	MD & Head of Marketing	N/A	N/A	N/A
Jihye Song	MD & Head of Cosmetics	N/A	N/A	N/A
Young Mahn Yoo	MD & Chief Production Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.

Corporate governance

Hugel, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.